New agent targeting Nectin-4 produces responses in nearly half of patients with advanced urothelial cancer
New agent targeting Nectin-4 produces responses in nearly half of patients with advanced urothelial cancer
PARP inhibitor olaparib as treatment for pancreatic cancer patients with BRCA gene mutations
Enzalutamide as treatment for men with mHSPC who have received testosterone suppression
Comment: Using enzalutamide will allow patients to avoid chemotherapy and steroids improving quality of life
Maintenance therapy with PARP inhibitor olaparib delays progression in patients with BRCA-related pancreatic cancer
Comment: It is essential to identify the BRCA gene in pancreatic cancer patients allowing them to be treated with an oral agent
AXL inhibitor bemcentinib in combination with chemotherapy exerts anti-leukaemic activity in AML patients
PARP inhibitors are a promising alternative to chemotherapy for patients with metastatic BRCA1 and BRCA2 breast cancer
Subcutaneous versus intravenous daratumumab administration in patients with relapsed or refractory multiple myeloma
MONALEESA-7: Results from phase III trial looking at ribociclib as an addition to endocrine therapy in advanced breast cancer
Ribociclib and endocrine therapy improves survival for pre-menopausal women with advanced breast cancer
Comment: The use of CDK 4/6 inhibitors now translates to a significant survival benefit in breast cancer treatment